UBS AM
GLUE icon

UBS AM’s Monte Rosa Therapeutics GLUE Stock Holding History

UBS AM’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$317K Buy
19,279
+18,709
+3,282% +$358K ﹤0.01% 2649
2025
Q4 		$8.94K Buy
+570
New +$7.68K ﹤0.01% 2873
2025
Q3 		– Sell
-24,100
Closed -$109K – 2409
2025
Q2 		$109K Hold
24,100
– – ﹤0.01% 2586
2025
Q1 		$112K Buy
+24,100
New +$148K ﹤0.01% 2595
2024
Q4 		– Sell
-24,100
Closed -$128K – 2698
2024
Q3 		$128K Buy
24,100
+8,500
+54% +$42.9K ﹤0.01% 2776
2024
Q2 		$58.3K Buy
+15,600
New +$79.5K ﹤0.01% 2781

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

UBS AM's GLUE Position: Q1 2026 in Review

UBS AM increased its Monte Rosa Therapeutics (GLUE) stake by 3,282% in Q1 2026, buying an estimated $358K and bringing the position to 19,279 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #2649.

UBS AM first reported a position in GLUE in Q2 2024 and has held it in 6 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • UBS AM held 19,279 shares of Monte Rosa Therapeutics worth $317K as of Q1 2026.
  • UBS AM bought 18,709 Monte Rosa Therapeutics shares in Q1 2026, an estimated $358K.
  • Monte Rosa Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2649 holding.
  • UBS AM first reported a position in Monte Rosa Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.